MedTrace Logo

Tailored Therapy for Clarithromycin-Resistant H. Pylori

NCT03431688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 782

Last updated 2025-09-22

No results posted yet for this study

Summary

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

PAM

treatment with PPI, metonidazole, amoxicillin

DRUG

PBMT

treatment with PPI, metonidazole, bismuth, tetracyclin

Sponsors & Collaborators

  • Kangdong Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • Woon Geon Shin · Kangdong Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-10-30
Completion
2020-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431688 on ClinicalTrials.gov